

# Incident and recurrent CUD diagnoses in patients with type 2 diabetes comparison between propensity–score matched cohorts at different follow–up time windows

Follow–up time window	Semaglutide cohort	Non–GLP1R agonist anti–diabetes medications cohort	HR (95% CI)
<b>Incident CUD (n=29,796/cohort)</b>			
8–month	0.17% (50)	0.36% (106)	0.45 (0.32–0.63)
1–year	0.23% (69)	0.46% (136)	0.48 (0.36–0.64)
2–year	0.41% (123)	0.70% (209)	0.55 (0.44–0.69)
3–year	0.55% (164)	0.90% (269)	0.61 (0.50–0.74)
<b>Recurrent CUD (n=243/cohort)</b>			
8–month	10.29% (25)	18.11% (44)	0.53 (0.32–0.86)
1–year	13.17% (32)	21.81% (53)	0.55 (0.36–0.85)
2–year	21.81% (53)	27.16% (66)	0.71 (0.50–1.02)
3–year	28.40% (69)	34.98% (85)	0.70 (0.51–0.97)

